TCM Limited scheduled its 82nd Annual General Meeting (AGM) for September 25, 2026, to approve financial statements showing a significant turnaround in profitability. The company reported a consolidated net loss of ₹599.6 million for the fiscal year ended March 31, 2026, reversing a net profit of ₹151.4 million recorded in the previous year.

The decline in earnings was driven by lower operational revenue and higher finance costs. Consolidated total income fell to ₹2,070.0 million from ₹3,047.5 million in the prior period. Meanwhile, total expenses stood at ₹2,672.5 million, reflecting increased employee benefit expenses and interest outlays.

Financial Performance

The standalone entity also reported a net loss of ₹363.4 million, compared to a profit of ₹326.4 million in the preceding year. Standalone total income was ₹1,853.3 million, while total expenses reached ₹2,219.6 million.

What the Numbers Show

The financial results reveal a sharp divergence between operating performance and non-operating income. In the previous year, the company benefited from a substantial write-back of liabilities amounting to ₹423.0 million, which significantly boosted other income. For the current year, this write-back dropped to ₹59.5 million, removing a key support for the bottom line. Additionally, finance costs surged to ₹192.4 million on a consolidated basis, up from ₹59.1 million in the prior year, indicating increased leverage or borrowing activity that weighed heavily on profitability despite relatively stable operating expenses.

Business Operations and Strategy

The company continues operations across solar power, medical diagnostics, cattle feed, and real estate. The chemical manufacturing unit at Mettur remains suspended due to financial constraints and raw material shortages. In real estate, the company has entered into a memorandum of understanding with Asset Homes TCM Townships Pvt. Ltd. for the joint development of an 11-acre land parcel in Kalamassery. Construction is expected to commence in FY27 subject to statutory approvals.

Corporate Governance and Dividend

The Board of Directors did not recommend any dividend for FY26 due to the losses incurred during the year. The AGM agenda includes the reappointment of Mrs. Rani Jose as a director retiring by rotation. Additionally, shareholders are sought to approve the reappointment of independent directors Mr. Gopalakrishnan Mahesh and Mr. Jose Jacob for a second term of five years each.

TCM Limited reported a narrowing of losses and significant revenue growth for the first quarter of FY27. The company posted a standalone net loss of ₹121.69 lakh for the quarter ended June 30, 2026, compared to a net loss of ₹147.88 lakh in the corresponding period of FY26. On a consolidated basis, the group recorded a net loss of ₹160.13 lakh, down from ₹235.26 lakh in Q1FY26.

Revenue from operations expanded sharply, reflecting improved operational activity across key segments. Standalone revenue rose 32% year-on-year to ₹402.01 lakh, up from ₹304.87 lakh in Q1FY26. Consolidated revenue grew even more robustly by 52% to ₹487.97 lakh, compared to ₹320.97 lakh in the prior year quarter.

Segment Performance

The company’s diversified portfolio saw mixed results, with the trading segment emerging as a key profit contributor while manufacturing faced headwinds.

The trading segment, which includes solar, healthcare, autocare, and audio products, delivered a positive segment result of ₹30.87 lakh, a significant improvement from a loss of ₹72.74 lakh in Q1FY26. Conversely, the manufacturing segment, despite contributing the largest share of revenue at ₹308.61 lakh, incurred a segment loss of ₹37.22 lakh, widening from a profit of ₹22.79 lakh in the same period last year. The real estate segment contributed ₹12.54 lakh to the bottom line, while the educational unit reported a modest profit of ₹2.61 lakh.

What the Numbers Show

A critical divergence exists between top-line growth and bottom-line performance. While consolidated revenue surged 52% year-on-year, total expenses increased by 16% to ₹653.85 lakh. More notably, finance costs rose 35% to ₹52.16 lakh from ₹38.54 lakh in Q1FY26. This disproportionate rise in interest expenses relative to revenue growth indicates that debt servicing costs are currently outpacing operational leverage, limiting the translation of higher sales into profitability.

Corporate Developments

During its board meeting held on August 13, 2026, TCM Limited approved several administrative matters alongside the financial results. The board recommended the reappointment of independent directors Mr. Gopalakrishnan Mahesh and Mr. Jose Jacob for a second term of five years, subject to shareholder approval at the upcoming annual general meeting. The 82nd Annual General Meeting is scheduled for September 25, 2026.

The unaudited financial results were reviewed by S G M & Associates LLP, the statutory auditors, who issued a limited review report stating that nothing came to their attention to cause them to believe the statements contained material misstatements.